Interaction with damaged vessel wall in vivo in humans induces platelets to express CD40L resulting in endothelial activation with no effect of aspirin intake.
暂无分享,去创建一个
Emanuela Falcinelli | Paolo Gresele | P. Gresele | S. Momi | E. Falcinelli | L. Bury | R. Rossi | Silvia Giannini | Loredana Bury | Giuseppe Guglielmini | Roberta Rossi | Stefania Momi | S. Giannini | G. Guglielmini
[1] R. Kroczek,et al. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. , 2001, Blood.
[2] W. Daniel,et al. Upregulation of CD40 and CD40 Ligand (CD154) in Patients With Moderate Hypercholesterolemia , 2001, Circulation.
[3] P. Lucidi,et al. Hyperglycemia-Induced Platelet Activation in Type 2 Diabetes Is Resistant to Aspirin but Not to a Nitric Oxide–Donating Agent , 2010, Diabetes Care.
[4] L. Jennings,et al. Regulation of CD40L (CD154) and CD62P (p-selectin) surface expression upon GPIIb-IIIa blockade of platelets from stable coronary artery disease patients. , 2010, Thrombosis research.
[5] A. Michelson,et al. Downregulation of the platelet surface glycoprotein Ib-IX complex in whole blood stimulated by thrombin, adenosine diphosphate, or an in vivo wound. , 1991, Blood.
[6] K. Mann,et al. Simvastatin Depresses Blood Clotting by Inhibiting Activation of Prothrombin, Factor V, and Factor XIII and by Enhancing Factor Va Inactivation , 2001, Circulation.
[7] W. Kuliczkowski,et al. Aspirin failure course during exercise and its connection with soluble CD40L. , 2007, Thrombosis research.
[8] P. Gresele,et al. Leukotriene B4 production by stimulated whole blood: comparative studies with isolated polymorphonuclear cells. , 1986, Biochemical and biophysical research communications.
[9] J. Freedman,et al. Plasma, serum, and platelet expression of CD40 ligand in adults with cardiovascular disease. , 2005, The American journal of cardiology.
[10] Y. Merhi,et al. Enhanced Levels of Soluble CD40 Ligand Exacerbate Platelet Aggregation and Thrombus Formation Through a CD40-Dependent Tumor Necrosis Factor Receptor–Associated Factor-2/Rac1/p38 Mitogen-Activated Protein Kinase Signaling Pathway* , 2010, Arteriosclerosis, thrombosis, and vascular biology.
[11] M. Gawaz,et al. Engagement of Glycoprotein IIb/IIIa (&agr;IIb&bgr;3) on Platelets Upregulates CD40L and Triggers CD40L-Dependent Matrix Degradation by Endothelial Cells , 2002, Circulation.
[12] F. Santilli,et al. Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus , 2010, Journal of thrombosis and haemostasis : JTH.
[13] R. Kroczek,et al. Activated Platelets Induce Tissue Factor Expression on Human Umbilical Vein Endothelial Cells by Ligation of CD40 , 1998, Thrombosis and Haemostasis.
[14] W. Koenig,et al. Effect of Rosiglitazone Treatment on Soluble CD40L in Patients With Type 2 Diabetes and Coronary Artery Disease , 2003, Circulation.
[15] J. J. Varo,et al. Adiponectin diminishes platelet aggregation and sCD40L release. Potential role in the metabolic syndrome. , 2010, American journal of physiology. Endocrinology and metabolism.
[16] J. Sampol,et al. Reevaluation of Trypsin-EDTA for Endothelial Cell Detachment before Flow Cytometry Analysis , 1996 .
[17] Patrick André,et al. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. , 2002, Circulation.
[18] Reinhold Förster,et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells , 1998, Nature.
[19] G. Stel,et al. A new model of human aortic endothelial cells in vitro. , 2000, Biochimie.
[20] A. Michelson,et al. vivo wound (see comments) whole blood stimulated by thrombin, adenosine diphosphate, or an in Downregulation of the platelet surface glycoprotein Ib-IX complex in , 2011 .
[21] J. Manson,et al. Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians' Health Study , 1992, The Lancet.
[22] J. Westwick,et al. Investigation of the Interaction of Blood Platelets with the Coagulation System at the Site of Plug Formation In Vivo in Man - Effect of Low-Dose Aspirin , 1987, Thrombosis and Haemostasis.
[23] D. Phillips,et al. Inhibitory Effects of Glycoprotein IIb/IIIa Antagonists and Aspirin on the Release of Soluble CD40 Ligand During Platelet Stimulation , 2003, Circulation.
[24] F. Santilli,et al. Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: effect of improved metabolic control , 2005, Diabetologia.
[25] AlbertSchömig,et al. Activated Platelets Induce Monocyte Chemotactic Protein-1 Secretion and Surface Expression of Intercellular Adhesion Molecule-1 on Endothelial Cells , 1998 .
[26] Semple,et al. Preanalytical requirements for flow cytometric evaluation of platelet activation: choice of anticoagulant , 1999, Transfusion medicine.
[27] C. Patrono,et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. , 1980, Thrombosis research.
[28] M. Wolzt,et al. Large amounts of vascular endothelial growth factor at the site of hemostatic plug formation in vivo. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[29] P. Gresele,et al. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. , 1987, The Journal of clinical investigation.
[30] N. Kleiman,et al. Soluble CD40 ligand in acute coronary syndromes. , 2003, The New England journal of medicine.
[31] E. Ongini,et al. A novel nitric oxide‐releasing statin derivative exerts an antiplatelet/antithrombotic activity and inhibits tissue factor expression 1 , 2005, Journal of thrombosis and haemostasis : JTH.
[32] A. Orlacchio,et al. Platelets Release their Lysosomal Content In Vivo in Humans upon Activation , 2000, Thrombosis and Haemostasis.
[33] G. Davı̀,et al. , Hypercholesterolemia : Effects of Statin Therapy Association Between Enhanced Soluble CD 40 L and Prothrombotic State in , 2002 .
[34] F. Cipollone,et al. Preprocedural Level of Soluble CD40L Is Predictive of Enhanced Inflammatory Response and Restenosis After Coronary Angioplasty , 2003, Circulation.
[35] S. Fiorucci,et al. Salicylates inhibit adhesion and transmigration of T lymphocytes by preventing integrin activation induced by contact with endothelial cells. , 1998, Blood.
[36] H. Weiss,et al. Studies of thromboxane B2, platelet factor 4, and fibrinopeptide A in bleeding-time blood of patients deficient in von Willebrand factor, platelet glycoproteins Ib and IIb-IIIa, and storage granules. , 1993, Blood.
[37] A. Becker,et al. CD40 ligand is selectively expressed on CD4+ T cells and platelets: implications for CD40–CD40L signalling in atherosclerosis , 2003, The Journal of pathology.
[38] D. Phillips,et al. Soluble CD40 ligand induces β3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[39] A. Connor,et al. The way I see it: House officers need formal career development , 2002 .
[40] D. Francisci,et al. HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction , 2009, AIDS.
[41] F. Santilli,et al. Thromboxane and prostacyclin biosynthesis in heart failure of ischemic origin: effects of disease severity and aspirin treatment , 2010, Journal of thrombosis and haemostasis : JTH.
[42] F. Sánchez-Jiménez,et al. Monocyte chemoattractant protein-1: a key mediator in inflammatory processes. , 2009, The international journal of biochemistry & cell biology.
[43] D. Simon,et al. GP IIb/IIIa inhibition with eptifibatide lowers levels of soluble CD40L and RANTES after percutaneous coronary intervention , 2004, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[44] P. Gresele,et al. Platelets release active matrix metalloproteinase‐2 in vivo in humans at a site of vascular injury: lack of inhibition by aspirin , 2007, British journal of haematology.
[45] K. Schrör,et al. Platelet CD40 ligand (CD40L) – subcellular localization, regulation of expression, and inhibition by clopidogrel , 2001, Platelets.
[46] N. Bayley,et al. Failure , 1890, The Hospital.
[47] H. Gold,et al. Cardiopulmonary Bypass Induces Release of Soluble CD40 Ligand , 2002, Circulation.
[48] Catherine Sudlow,et al. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.
[49] W. Daniel,et al. Platelets contribute to enhanced MCP-1 levels in patients with chronic heart failure , 2007, Heart.
[50] R. Hynes,et al. CD40L stabilizes arterial thrombi by a β3 integrin–dependent mechanism , 2002, Nature Medicine.